The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.
Hospitals urge regulators to halt drugmakers’ expanded 340B data policies
By Awais
